BioArctic: Outlicenses PyroGlutamate-amyloid-beta antibody program to BMS - Redeye
Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArctic's PyroGlutamate-amyloid-beta antibody program and give our initial take.
ANNONS
Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArctic's PyroGlutamate-amyloid-beta antibody program and give our initial take.